Suzhou Zelgen Biopharmaceuticals Co., Ltd.
public_traded
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is publicly traded on SHH under ticker 688266.SS.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.